收藏切换
The combined application of PBPK model and PopPK model in the dose selection of pediatric drug development: an example of rivaroxaban
收藏切换
PDF
Wei-zhe JIAN, Rong CHEN, Tian-yan ZHOU*
Acta Pharmaceutica Sinica | 2022, 57(10) : 3157 - 3162
Less
收藏切换
Acta Pharmaceutica Sinica | 2022, 57(10): 3157-3162
Reviews
The combined application of PBPK model and PopPK model in the dose selection of pediatric drug development: an example of rivaroxaban
Full
Wei-zhe JIAN, Rong CHEN, Tian-yan ZHOU*
Affiliations
  • Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
Published: 2022-10-12 doi: 10.16438/j.0513-4870.2022-0880
Outline
收藏切换

Model-informed drug development (MIDD) in the development of pediatric drugs is drawing more and more attention due to the insufficiency of subjects, lack of research on ontogeny, and the limitation of ethic. The core of MIDD used for dose selection includes the population pharmacokinetic (PopPK) model and physiologically based pharmacokinetic (PBPK) model, as well as model-based simulation and prediction. PBPK model has the advantage of predicting the optimal pediatric dose before the clinical trials and has the ability of extrapolation from adult model to pediatric model. PopPK model characterizes the pediatric PK feature based on the analysis of clinical data and can be used to explore the significant covariates, which is a power tool for individualized medicine in children. With their own advantages and disadvantages, PBPK and PopPK model should be jointly used in the pediatric drug development to refine the dose regimen for children at different ages. In this study, the pediatric drug development of rivaroxaban was taken as an example to introduce the combined application of PBPK model and PopPK model in the design and validation of pediatric dose regimen in Phase Ⅰ, Ⅱ and Ⅲ trials, which may provide reference to MIDD in other pediatric drug development.

model-informed drug development  /  pediatric drug  /  population pharmacokinetic model  /  physiologically based pharmacokinetic model  /  rivaroxaban
Wei-zhe JIAN, Rong CHEN, Tian-yan ZHOU. The combined application of PBPK model and PopPK model in the dose selection of pediatric drug development: an example of rivaroxaban[J]. Acta Pharmaceutica Sinica, 2022 , 57 (10) : 3157 -3162 . DOI: 10.16438/j.0513-4870.2022-0880
Year 2022 volume 57 Issue 10
PDF
164
63
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2022-0880
  • Receive Date:2022-07-19
  • Online Date:2025-12-24
  • Published:2022-10-12
Article Data
Affiliations
History
  • Received:2022-07-19
  • Revised:2022-08-17
Funding
Affiliations
    Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-0880
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT